SCHEMBL6138451

SCHEMBL6138451

CCOC(=O)CCCCC(=O)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
MEN1 O00255 3/20 0.51
LMNA P02545 3/20 0.51
HPGD P15428 4/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
MAPT P10636 3/20 0.50
CXCR3 P49682 1/20 0.49
ALDH1A1 P00352 3/20 0.49
TSHR P16473 3/20 0.49
HTT P42858 1/20 0.49
MAPK1 P28482 1/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 2/20 0.46
POLB P06746 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B3 P37058 3/20 0.44
CYP4F2 P78329 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10950721 0.95 KMT2A (0.54) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL7460876 0.94 KMT2A (0.53) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL11039344 0.94 KMT2A (0.53) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL7457718 0.94 KMT2A (0.53) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL2743413 0.92 KMT2A (0.54) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL11834763 0.91 KMT2A (0.60) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL10596300 0.86 KMT2A (0.65) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL3382930 0.85 L3MBTL1 (0.59) KMT2AMEN1LMNAHPGDL3MBTL1
SCHEMBL3381682 0.84 HDAC1 (0.61) KMT2AHPGDL3MBTL1MAPTALDH1A1
SCHEMBL4263364 0.83 SMN1; SMN2 (0.56) KMT2AMEN1LMNAHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119305-A1 Il-6 production inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-02 US disclosed
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM KMT2A 491/4885MEN1 111/4885LMNA 714/4885
US-20050119305-A1 Il-6 production inhibitors IL6, IL6ST, PADI6 KMT2A 829/4885MEN1 253/4885LMNA 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.